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Abstract
Objectives The aim of this systematic review was to examine the characteristics
of effective lifestyle modification interventions designed for patients with newly
diagnosed type 2 diabetes mellitus (T2DM) in order to determine elements that
have the potential to be delivered in the community pharmacy setting.
Key findings Seven studies, comprising three each of the interventions diet
and structured education and one of supported exercise, were identified. Inter-
ventions were conducted in hospital diabetes clinics and clinics situated in both
urban and rural areas. Interventions were delivered face to face by highly skilled
personnel including physicians, nurses and dietitians. Duration of interventions
ranged from 3 months to 5 years.
Summary Structured education and dietary interventions in newly diagnosed
type 2 diabetes effectively controlled blood glucose levels without pharmacolog-
ical intervention. Important characteristics included face to face, individualised
and multicomponent interventions with a duration of at least 6 months. These
characteristics demonstrate potential for delivery in a community pharmacy
setting, given its current involvement in delivering face to face, individual ser-
vices with diet and lifestyle components. Further research is required to provide
evidence for ideal intervention duration and frequency as well as training
requirements for pharmacists.
Introduction
Diabetes mellitus, highlighted as a global burden by the
World Health Organisation, is one of the most common
causes of major health and development challenges in the
21st century.[1–3] Globally, it is estimated that 422 million
people are living with diabetes, a prevalence that has
almost quadrupled since 1980.[2] This dramatic rise is lar-
gely attributed to an increase in type 2 diabetes mellitus
(T2DM), primarily driven by modifiable risk factors
including obesity and physical inactivity.[2,4,5] The pro-
gression of T2DM, often associated with the development
of disabling and life-threatening complications, also
threatens many health economies.[6] In England, where
almost 3.1 million people are diagnosed with diabetes,[7]
the National Health Service spends approximately
£8.8 billion of its total annual expenditure on the man-
agement of T2DM.[8]
The management of T2DM requires a comprehensive
approach to care including lifestyle modification and self-
management strategies. At diagnosis, treatment guidelines
recommend the initiation of pharmacological therapy,
primarily metformin.[9,10] However, highly motivated
patients with blood glucose levels near target are often
given the opportunity to engage with lifestyle changes for
a period of 3–6 months before embarking on pharma-
cotherapy.[11] In this medication-na€ıve population, the
non-pharmacological interventions of education and sup-
port for making diet and physical activity modifications
form an important element for achieving successful blood
glucose control.[9,11] However, most of the evidence for
these interventions is in the context of preventing disease
progression and complications in the population with
established T2DM.[12–16]
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Structured diabetes education in self-management and
lifestyle changes is the cornerstone of non-pharmacologi-
cal support for newly diagnosed people.[9,11,17] The time
of diagnosis is considered a critical point for structured
education to be offered to individuals and/or their car-
ers.[9,18]. However, structured evidence-based education
programmes are poorly attended. In the United Kingdom,
recent figures demonstrate that 16.7% of people with
newly diagnosed T2DM were offered education pro-
grammes with only 3.6% attending.[19] Similar problems
of engagement have been identified in other countries
such as the USA[20] and Germany, where almost 30–50%
of eligible patients do not participate in diabetes educa-
tion.[21,22] A diverse range of barriers to engaging with
education programmes have been reported including pro-
gramme timing, location, availability of transport and
flexibility of programme delivery.[23,24] A number of
strategies for improving participation in diabetes educa-
tion have been suggested including physician endorsement
of the programmes to patients.[25] However, in the United
Kingdom, despite a significant increase in the number of
referrals by physicians, attendance to structured education
has remained <10%.[26]
There is therefore a need to explore new ways of deliv-
ering diabetes education in order to increase participation
rates. In England, community pharmacy has been recog-
nised for its accessibility, particularly to highly deprived
populations and ethnic minority groups.[27] In these pop-
ulations, obesity, the greatest modifiable risk factor for
T2DM, has been shown to have the highest prevalence.[5]
Community pharmacy setting could therefore be well
placed to target low participation in this population. In
England, current use of the community pharmacy setting
in diabetes is primarily focused on established diabetes,
with the provision of enhanced services such as medicine
use reviews.[28,29] The involvement of community phar-
macy in newly diagnosed diabetes is limited to the provi-
sion of the New Medicines Service, a service designed to
improve adherence and persistence of newly prescribed
medicines.[29,30] Community pharmacies in England may
also provide opportunistic lifestyle interventions such as
weight management, smoking cessation and brief alcohol
interventions.[31,32] However, none of these interventions
are tailored specifically to T2DM or include diabetes edu-
cation. With evidence regarding the role of community
pharmacists in established diabetes demonstrating positive
clinical outcomes, there is potential for community phar-
macists to be involved in the management of people
newly diagnosed with type 2 diabetes.[33–38]
In order to explore whether community pharmacy has
the potential to provide adequate support to patients who
are newly diagnosed and medication na€ıve, there is a need
to explore the characteristics of effective interventions in
this population. The present systematic review aimed to
examine the characteristics of successful diet and lifestyle
interventions designed for patients with newly diagnosed
T2DM such as type of intervention, style of delivery,
resources, training requirements and settings in order to
determine elements that have the potential to be delivered
in the community pharmacy setting.
Methods
A narrative systematic review of published primary research
exploring diet and lifestyle interventions in adults newly
diagnosed with T2DM was performed. The protocol for
this systematic review was registered on PROSPERO.
Search strategy
Relevant electronic databases were reviewed from incep-
tion to the 31st of March 2015 including, the Cochrane
Central Register of Controlled Trials, Medline, EMBASE,
AMED, Web of Science, SCOPUS and CINAHL Com-
plete. The searches were re-run from inception to 24/08/
2018 to find any additional work that might warrant
inclusion. A search strategy limited to the English lan-
guage was developed and modified for each database
according to the medical subject headings used. Reference
lists of all potentially relevant studies identified were hand
searched for other potentially eligible studies. The search
terms and a MEDLINE search strategy can be viewed in
the supplementary file (Appendix S1).
Study selection
The study population included adults (>18 years) with
newly diagnosed T2DM. Participants were considered
‘newly’ diagnosed if they were within the first 12 months
of diagnosis at the start of the trial.[39] Duration of diag-
nosis was determined at recruitment stage by the clinical
trial research team as described in each paper. For the
purposes of exploring non-pharmacologically managed
T2DM, only participants who were medication na€ıve were
included. Studies were eligible regardless of setting in
which they had been conducted. This was to ensure a
wide range of interventions were captured.
Eligible interventions included diet, exercise, weight loss
or education with usual practice or standard care as an
acceptable comparator. Studies had to report at least one
of the following outcomes of interest: time to initiation of
medication treatment, glycosylated haemoglobin (HbA1 or
HbA1c) (mmol/mol), weight (kg), body mass index (BMI)
(kg/m2)), blood pressure (mmHg) and total cholesterol
(mmol/l). To be included, the study design had to be a
randomized controlled trial, non-randomized controlled
© 2019 The Authors. International Journal of Pharmacy Practice
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trial or controlled before-and-after study. Studies were
excluded if they were focused on medication, for example
medication reviews, effects of prescription medication or
dietary supplements.
Screening and data extraction
An initial title screen was performed by the primary
reviewer (TK) to exclude any records identified through
the search that clearly did not meet the inclusion criteria.
Following the title screen, two reviewers (TK plus MT or
DB) independently reviewed the abstracts of the remain-
ing papers. The full papers identified as potentially eligible
from the abstract screen were then retrieved and screened
for eligibility against the inclusion criteria independently
by two review authors (TK plus MT or DB). Any dis-
agreements were resolved through discussion and if neces-
sary by arbitration by a third reviewer (MT or DB). The
overall inter-rater agreement for the full-text screening
process was calculated using Cohen’s kappa coefficient.[40]
For each eligible paper, two reviewers (TK plus MT or
DB) independently extracted data. Variations in data
extraction were resolved by consensus, referring back to
the original data. The data from the eligible studies were
extracted using a tailored extraction form based on the
EPOC data collection checklist.[41]
The following data were extracted:
 Publication details: title, authors, journal, year of publi-
cation, volume, pages.
 Population and settings: population description, setting,
inclusion criteria, exclusion criteria, and recruitment
methods.
 Methods: aim of the study, design and duration of par-
ticipation.
 Participants: total number at the start of the trial, age,
gender, ethnicity, socio- economic status, comorbidities,
time since diagnosis and other treatment received.
 Intervention: type of intervention, setting, description of
the intervention, description of standard care, duration
of intervention, timing (e.g. frequencies of contact),
delivery (e.g. intensity), method of follow-up, providers
and resources requirements.
 Outcomes: whether reported, measurement tool/
method, unit of measurement, length of follow-up,
number or times of follow-up measurement.
 Analysis: number of withdrawals/exclusions/lost to fol-
low-up (retention).
 Authors key results and conclusion.
Quality assessment
The methodological quality of each included paper was
critically appraised using the EPOC criteria.[42] Each study
was scored low, high or unclear (if not specified in the
paper) for each of the criteria. Two reviewers (TK and
MT) carried out the assessment independently. Blinding
was not assessed as a quality criterion due to inability to
blind participants and the objective nature of the out-
come measure. The results were compared and any dis-
crepancies resolved by discussion. The overall inter-rater
agreement for the quality assessment was calculated using
Cohen’s kappa coefficient.[40] The quality assessment was
used to determine the level of relevance of interventions
to current practice.
Data synthesis
Due to the diversity of interventions in the included stud-
ies such as types of interventions and their duration, a
narrative synthesis was adopted to summarise the
results.[43] The textual approach of the synthesis provided
an analysis of the relationships within and between
studies and an overall assessment of the robustness of the
evidence.
Results
Search results
The flow of studies through the screening process is pro-
vided in Figure 1. The main reason for exclusion at full-
text screening of the 87 articles was that study partici-
pants were not newly diagnosed and/or medication na€ıve
at the start of the trial. The overall inter-rater agreement
for the full-text screening process was high, achieving a
kappa score of 0.84. In total, seven published trials met
the inclusion criteria and were thus eligible for data
extraction.
Intervention characteristics
Types of intervention
The main characteristics of the population and
interventions in the included studies are provided in
Tables 1 and 2, respectively. All seven studies were ran-
domised controlled trials conducted in Europe.[44–50] The
study sample sizes ranged from 21 to 1139 and included
participants with a mean age ranging from 46 to 56 years.
Interventions were supported exercise,[44] diet[47,49,50] and
structured education.[45,46,48]
Structured education was delivered in either a group or
a individual setting. Laitinen et al.[48] reported a
12-month individual education intervention delivering
tailored intensified dietary education following a 3-month
basic education period offered to all study participants.
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Heller et al. reported a 6-month group education inter-
vention with sessions attended by four to six intervention
participants, each with their spouse or friend.[46] The
intervention which aimed to promote weight loss, encour-
aged healthy eating by teaching participants to make
appropriate food choices. The study also included a
6-month follow-up post-intervention period. Hanefeld
et al.[45] reported a 5-year multi-interventional intensified
group education consisting of diet and physical activity
interventions to promote weight loss as well as smoking
cessation and alcohol interventions. Dietary interventions
were aimed at restriction of carbohydrates, cholesterol
and/or fat,[47,49] and increasing knowledge and
appropriate consumption of low glycaemic index (GI)
foods.[50] The intervention reported by Esposito et al.[49]
also included physical activity advice which was offered to
all study participants. Backx et al.[44] reported a 12-week
supported exercise intervention consisting of a cardiores-
piratory phase and interval training delivered at individu-
alised training intensities.
Settings
Five studies defined intervention settings as diabetes clin-
ics in secondary care[46–50] and one in diabetes clinics in
urban or rural areas.[45] Backx et al.[44] who reported the
Figure 1 Adapted PRISMA flow diagram of study selection.
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supported exercise intervention was the only study which
did not mention the intervention setting.
Delivery
All interventions were delivered face-to-face with some
including telephone contact. Backx et al. used telephone
contact to check on the progress of the standard care
unsupported exercise participants and Heller et al. used
telephone contact in the post-intervention follow-up per-
iod.[44,46] Dietary, physical activity and weight loss recom-
mendations were delivered using a variety of methods
including, visual, oral and written instructions.[45,46,48–50]
Both group and individual education interventions used
behaviour modification strategies such as goal setting to
encourage weight loss or diet modification.[46,48] Heller
et al.[46] (group education) also used progress mapping of
weight, group discussion and attendance with spouse or
friends. Laitinen et al.[48] (individualised education)
included individually tailored dietary instructions, practi-
cal food preparation and behaviour modification strate-
gies, for example self-motivation and recognition of
situations which may pose a challenge to dietary control.
Frequency, duration and follow-up
The shortest intervention with the highest frequency of
contact was reported by Backx et al.[44] who delivered 60-
min supported exercise sessions, three times a week for
12 weeks. The shortest structured education intervention
lasted for 6 months [46] and the longest lasted for
5 years.[45] Structured education and diet interventions
were delivered at intervals ranging from three weekly to
three monthly.[44–47,49,50] Duration of sessions was only
described by Heller et al.[46] who reported delivering 90-
min structured education sessions. The primary follow-up
method used was clinic visits with self-reporting methods
such as diaries used to record adherence to dietary
recommendations.[44,47,50]
Resources and training requirements
Supported exercise was delivered by qualified exercise
physiologists and physiotherapists and dietary advice was
delivered primarily by dieticians, clinical nutritionists and
diabetologists.[44–49] Diabetes education was delivered by
diabetes nurse specialists.[46,48] Physicians were primarily
Table 1 Characteristics of study participants
Study Intervention
Total (intervention/
control) (n) Age (years)
Gender
(% males)
Time since
diagnosis
Significant baseline
differences
between groups
Backx 2011[44] Supported exercise 21 (11/10) Median (range):
59.6 (44–69)
79% <3 months None
Esposito 2009[49] Diet programme 215 (108/107) Mean
Intervention: 52.4
Control: 51.9
49% Newly diagnosed None
Frost 1994[50] Diet programme 51 (25/26) Mean (range)
Intervention: 54 (52–56)
Control: 56 (53–59)
71% Newly diagnosed Cholesterol
Hanefeld 1991[45] Multi- intervention
group education
1139a (382/378) Mean (SD):
Intervention: 46.6  5.6
Control: 46.2  7.0
58% Newly diagnosed Fasting blood
glucose
Heller 1988[46] Group education 87 (40/47) Mean (95% CI):
Intervention: 56.5 (55–58)
Control: 56.4 (53-59.9)
48% Newly diagnosed None
Hockaday 1978[47] Diet programme 93 (39/54) Mean (range):
Intervention: 50 (24–65)
Control: 53 (22–65)
56% Newly diagnosed % over ideal
body weight
Laitinen 1993[48] Individualised
education
86 (40/46) Mean (SD):
Intervention:
50.7  7.7 (men)
Intervention:
53.7  6.3 (women)
Control:
54.0  6.6(men)
Control:
54.4  6.4 (women)
57% Newly diagnosed None
aParticipants in this study were randomised to 3 arms including control (378), Intensified Health Education plus placebo (IHE) (382) and clofibric
acid (379). For the purposes of this review we only examined the findings of participants in the control and IHE group.
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involved at diagnosis and initial clinic visits but had very
little to do with delivering the interventions.[46,48] Train-
ing was only mentioned by Hanefeld et al.[45] who trained
all participating staff to ensure standardisation of the
intervention but there was no detail of what the training
entailed.
Outcome measures
The outcome measures for each reported study are sum-
marised in Table 3. The structured education intervention
reported by Hanefeld et al.[45] reported a significantly
smaller proportion of participants initiated on medication
treatment at 2- and 5-years (9%, 33%) compared to stan-
dard care (34%, 54%) (P < 0.01). Similarly, the Mediter-
ranean diet programme reported by Esposito et al.
reported a significantly smaller proportion of participants
initiated on medication at 18 months and 4 years (12%
and 44%, respectively) compared to standard dietary
advice (24% and 70%, respectively).[49] These were the
only studies to have reported this outcome measure of
interest. Secondary measures of interest reported by the
studies, including blood pressure, BMI and cholesterol,
were not used for the purposes of this review as data
included participants who had been initiated on diabetes
medication treatment during the intervention period.
The group and individual structured education interven-
tions reported by Heller et al. and Laitinen et al., respec-
tively, were the only interventions reporting clinically
significant reductions in both weight (P < 0.002 and
P = 0.05 respectively) and HbA1/HbA1c (P < 0.001 and
P = 0.053, respectively) compared to standard care.[46,48]
Heller et al. who reported a 6-month education intervention
with a 6-month follow-up period reported weight reductions
which remained significantly greater than standard care dur-
ing both the intervention and the follow-up period.[46]
However, the reduction in HbA1, which reached normal
levels during the 6-month intervention period, was not
maintained following the post-intervention follow-up per-
iod.[46] At 12 months, the HbA1 levels of the intervention
group not only reverted to diabetic levels but were also simi-
lar to the standard care group.[46] Laitinen et al.[48] reported
a 3-month basic education offered to all the study partici-
pants which resulted in significant weight (P < 0.01) and
HbA1c (P < 0.001) reductions in both groups. However,
during the 12-month intervention period, only individuals
in the intervention group achieved further weight and HbA1c
reductions with overall significant reduction at the end of
the 15-month period ((P < 0.05) and ((P = 0.053)).[48]
Total cholesterol was reported by Backx et al. in the
supported exercise intervention, Hockaday et al. in the
modified-fat diet, Frost et al. in the low GI diet interven-
tion and Laitinen et al. in the individual structured
education intervention.[44,47,48,50] Of the four interven-
tions to have reported total cholesterol levels, only Hock-
aday et al. and Frost et al. reported significant reductions
compared to standard care (P = 0.01 and P < 0.05,
respectively). The modified-fat diet intervention, which
consisted of moderate carbohydrate content, produced no
additional benefits in achieving clinically significant
weight loss when compared to standard low-carbohydrate
diet.[47] The supported exercise intervention, despite pro-
ducing significant within group differences, had no
advantage over standard care in reducing BMI and HbA1c
in medication-na€ıve patients.[44] None of the studies
reported blood pressure as an outcome.
Quality assessment
A methodological quality assessment of the included stud-
ies was conducted, the findings of which are reported in
Table 4. The overall inter-rater agreement was substantial
(kappa = 0.73). Sources of bias included significant base-
line differences in outcomes of interest (Hanefeld et al.,
Hockaday et al. and Frost et al.) and lack of reporting
subsequent adjusted analysis (Hockaday et al. and Frost
et al.). Hockaday et al. and Esposito et al. who reported
using the same dieticians and/or nutritionists for deliver-
ing both the intervention and the standard care partici-
pants were rated high for contamination bias.[47,49]
Unclear reporting of methods of randomisation and allo-
cation concealment in most of studies precluded an ade-
quate assessment of selection bias. Additionally, due to
incomplete reporting, the only two studies addressing the
outcome ‘initiation of medication treatment’ (Hanefeld
et al. and Esposito et al.) could not be examined fully in
order to investigate the effects of the intervention on the
other outcomes in medication-na€ıve participants.[45,49]
Overall study attrition, assessed as incomplete data, was
rated medium with most studies reporting low attrition
rates. Four studies (Backx et al., Heller et al., Esposito
et al. and Frost et al.) accounted for all randomised par-
ticipants. In these studies, the proportion of missing data
was similar in the intervention and control groups with
reasons for attrition including dropouts, hyperglycaemic
events, uncontrolled diabetes and death. However, the 5-
year intervention reported by Hanefeld et al. was rated
high risk of bias as it only accounted for those who failed
to complete the study due to death. Hockaday et al. and
Laitinen et al. were rated unclear as they reported the
same number of participants at baseline and in the analy-
sis and did not specify any attrition. Overall risk of bias
across studies was rated medium and evidence deemed
reliable for the purposes of extraction of effective compo-
nents of lifestyle modification interventions in newly diag-
nosed type 2 diabetes.
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Discussion
This review found that both structured education inter-
ventions and dietary interventions in newly diagnosed
T2DM effectively controlled blood glucose levels without
pharmacological intervention and positively affected clini-
cally important outcomes such as weight and
HbA1c.
[45,46,48,49] Characteristics of effective interventions
included face to face, individualised, multicomponent
education and diet interventions with a duration
>6 months.
Rigorous systematic review methods were adopted for
the conduct and reporting of this review. To minimise
the risk of bias and errors, data screening, extraction and
quality assessment were performed by two independent
reviewers. The overall inter-rater agreement for screening
and extraction (using Cohen kappa)[40] was good, achiev-
ing a kappa score of 0.84. Although the heterogeneity of
included studies precluded a meta-analysis, findings are
relevant to current practice and guidance has been pro-
vided regarding potential diabetes service innovations in
community pharmacy settings.[9,11] A limitation of the
review is the exclusion of non-English studies and the
limited effort made in contacting corresponding authors
for intervention details that were not included in the writ-
ten reports.[44,45,49] Additionally, although the risk of bias
across studies was rated medium, clinicians should exer-
cise caution when consulting evidence from this review to
inform future practice due to the lack of recent studies
conducted in primary care settings.
The community pharmacy setting
In clinical practice, intervention setting is amongst the
most important characteristics due to its potential to
influence uptake and attrition.[1,23–26,51,52] In this review,
two of the education interventions which demonstrated
positive clinical outcomes were delivered in hospital out-
patient settings.[46,48] Hospital settings may possess ideal
characteristics for the implementation of diabetes inter-
ventions and achieve desired clinical outcomes but they
often achieve a lower reach of the targeted populations
than primary care settings.[51] Primary care settings
have also demonstrated lower attrition rates than hospital
settings.[51]
In recent years, in meeting primary care demands, the
need to deliver diabetes education in alternative and con-
venient settings such as community pharmacies has been
acknowledged.[18] The 5-year education intervention
described in this review, conducted in both rural and
urban areas[45] and the 4-year dietary intervention con-
ducted in a city-based university clinic,[49] suggests that
both local and high street community pharmacies couldTa
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be well placed to deliver effective interventions. Addition-
ally, the community pharmacy team, which tends reflect
the culture of the local population, could play an impor-
tant role in engaging ethnic minorities and other hard to
reach groups thus also addressing cultural barriers identi-
fied by research.[23,51] In England, delivering diabetes
education in community pharmacy setting would be in
line with the current focus for the future of community
pharmacy[53] to be a facilitator of personalised care for
people with long-term conditions. However, to date,
although community pharmacy has been identified as a
favourable setting for the delivery diabetes education
in countries such as the USA,[18,54] community pharma-
cies in England do not offer any diabetes education
interventions.
The positive clinical outcomes of education interven-
tions in this review demonstrate the potential to support
people who are motivated to try non-pharmacological
options before embarking on pharmacotherapy.[9,11,17] In
this review, education interventions consisting of more
than one component including diet, exercise, smoking
cessation and alcohol interventions seemed to achieve
wider clinical benefits in addition to effective blood glu-
cose control in the management of T2DM, when com-
pared to interventions focused on single components
alone.[44,47,50] Therefore, based on this evidence[45,55] and
in line with management guidance,[9] community phar-
macy-based education interventions would have to deliver
multicomponent diabetes education interventions. With
community pharmacy currently delivering services such as
smoking cessation, brief alcohol interventions and exercise
advice, there is a potential to design education-based
intervention without extra training requirements on these
elements.[31]
When exploring the potential for community pharmacy
to deliver diabetes education, it is also important to
consider delivery characteristics of interventions that have
shown effectiveness in controlling blood glucose in newly
diagnosed type 2 diabetes. Majority of the interventions
described in this review primarily used face-to-face delivery
including one which also used telephone calls in the follow-
up period. Face-to-face delivery has been shown to predict
an increased likelihood of efficacy in diabetes education.[15]
Face-to-face interventions, a commonly used delivery style
in community pharmacy, would therefore be a more
favourable option for this setting. The use of follow-up tele-
phone calls, also used in community pharmacy interven-
tions such as the New Medicine Service,[29,30] could also be
easily implemented. Based on the evidence in this review,
both group and individual education interventions demon-
strated positive clinical outcomes, a finding in line with
other research evidence.[16,56] Generally due to cost-effec-
tiveness and the added advantage of patient networking,
group-based education is more widespread and recom-
mended as the choice delivery method in current treatment
guidelines.[57,58] However, group-based interventions have
been listed amongst the barriers to the uptake of diabetes
education.[52] NICE guidance for the management of
T2DM acknowledges that group sessions may not be popu-
lar with all patients and thus recommends the provision of
individualised education for people unable or unwilling to
participate in group education.[9] Therefore, based on this
finding and in line with guidance, community pharmacy,
which primarily delivers individualised interventions, could
perhaps serve as an alternative option for a population
which prefers individualised education. However, the cost-
effectiveness of delivering individualised community phar-
macy-based education would have to be considered.
Important intervention characteristics such as duration
and frequency of contact described in this review, largely
differed from current guidelines.[9,17] The interventions
included in this review generally had a longer duration
Table 4 Quality assessment of included studies
Study Randomisation
Allocation
concealment
Similar
baseline
characteristics
Similar
baseline
outcomes
Incomplete
data
Blinding
of
assessors Contamination
Selective
outcome
reporting
Other
bias
Backx 2011[44] Unclear Unclear Low Low Low Low Low Low Low
Esposito 2009[49] Computer-
generated
random
number
sequence
Low Low Low Low Low High High Low
Frost 1994[50] Random
number
tables
Unclear High High Low Low Unclear Low Low
Hanefeld 1991[45] Unclear Unclear High Low High Unclear Unclear High Low
Heller 1988[46] Unclear Unclear Low Low Low Low Low Low Low
Hockaday 1978[47] Unclear Unclear High High Unclear Low High Low Low
Laitinen 1993[48] Unclear Unclear Low Low Unclear Low Low Low Low
© 2019 The Authors. International Journal of Pharmacy Practice
published by John Wiley & Sons Ltd on behalf of Royal Pharmaceutical Society
International Journal of Pharmacy Practice 2019, 27, pp. 3--16
12 Newly diagnosed T2DM lifestyle interventions
and higher frequency of contact than current practice
guidance which recommends a single education interven-
tion at the time of diagnosis with annual reinforcement.[9]
Evidence shows that whilst single education interventions
may improve weight loss and physical activity levels in the
short term, they may not have any short or long-term
effects on glycaemic control.[59,60] Previous research also
suggests that increased contact time between participant
and educator decreases glycaemic levels, with a decrease of
1% in HbA1c for every additional 23.6 h.
[12] Current com-
munity pharmacy interventions vary in both duration and
frequency. For example, duration of services include
ongoing (e.g. medicines use reviews),[28,29] 12 week (e.g.
smoking cessation)[31,32] and one-off interventions (e.g.
diabetes screening). Frequency of contact also ranges from
annual (e.g. medicine use review),[28,29] two weekly (e.g.
new medicines services)[29,30] and weekly contact (e.g.
smoking cessation).[31,32] The variation displayed with
current interventions delivered in the community phar-
macy setting demonstrates potential to deliver diabetes
education interventions with longer duration and regular
frequency. Such interventions could also be linked with
regular visits to pharmacies for other prescription or
over-the-counter services.
Intervention facilitators and delivery skills are also
important factors to consider in the delivery of structured
education.[61] In this review, highly skilled personnel
including physicians, diabetes nurses, dietitians and nutri-
tionists were used to deliver the interventions. Although
this reflects the multidisciplinary approach recommended
by evidence,[62] the interventions did not reflect more
recent guidelines which demonstrate the expansion of the
role of facilitators over the recent years to include other dis-
ciplines such as pharmacists.[61] In the United States, the
2017 national standards for diabetes self-management edu-
cation and support (DESMES) recommends that at least
one of the team members responsible for facilitating
DESMES services should be a registered nurse, registered
dietitian nutritionist or pharmacist with training and
experience.[61] Using community pharmacists as diabetes
education facilitators could address barriers to attendance
identified by research such as comorbidities and cultural
beliefs.[23] People with T2DM often have comorbidities such
as hypertension and high cholesterol which require regular
medication often dispensed in community pharmacies.[9]
Therefore, established relationships between patients and
their pharmacists could be of potential benefit in decreasing
attrition rates in education interventions.[51]
The training requirements for diabetes education facili-
tators were not clearly described in the interventions
included in this review. However, due to the growing
recognition of pharmacists as diabetes educators, particu-
larly in the United States and Australia, courses have been
designed to support this additional training need.[54,63]
Evidence supports the need for facilitators to have spe-
cialised clinical knowledge in diabetes and behaviour
change principles.[61,64] In England, although a thorough
assessment of training requirements for community phar-
macists may need to be undertaken, current established
diabetes courses designed for healthcare professionals[65]
and training programmes for diabetes educators[66] could
be used to ensure that pharmacists have both specialised
clinical knowledge and behaviour change skills. Behaviour
change strategies identified by this review such as goal set-
ting, and progress mapping may also shed some light into
skills needed to deliver successful interventions.[67–70]
Conclusion
Structured education and dietary interventions in newly
diagnosed type 2 diabetes effectively controlled blood glu-
cose levels without pharmacological intervention. Impor-
tant characteristics included face to face, individualised
and multicomponent interventions with a duration of at
least 6 months. These characteristics demonstrate poten-
tial for delivery in a community pharmacy setting, given
its current involvement in delivering face-to-face individ-
ual services with diet and lifestyle components. Further
research is required to provide evidence for ideal
duration and frequency of education interventions for
this population as well as training requirements for
pharmacists.
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